Abstract
Thrombocytosis has been feared as a source of thrombotic complications during the conduct of cardiopulmonary bypass (CPB) for patients undergoing cardiac procedures. We present a patient urgently requiring repair/replacement of three heart valves that had preexisting myelofibrosis with thrombocytosis (platelet count of 800,000 per µl) and neutrophilia (40,000 per µl). Despite achieving an activated clotting time > 500 s with heparin and antithrombin concentrate administration prior to CPB, the pump oxygenator and reservoir demonstrated significant clot just prior to restoration of the patient’s circulation. The patient subsequently suffered a severe protamine reaction that was successfully managed. A review of the literature of similar patients and the relevant cellular and biochemical mechanisms in this setting are presented, with potential therapeutic approaches to prevent such complications noted.
Original language | English (US) |
---|---|
Pages (from-to) | 1220-1226 |
Number of pages | 7 |
Journal | Journal of Thrombosis and Thrombolysis |
Volume | 52 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2021 |
Keywords
- Cardiopulmonary bypass
- Neutrophilia
- Platelet factor 4
- Thrombocytosis
- Thrombosis
ASJC Scopus subject areas
- Hematology
- Cardiology and Cardiovascular Medicine